Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The "Budesonide Market Size, Forecast, and Drug Insight - 2032" report has been added to ResearchAndMarkets.com's offering.
The report provides comprehensive insights about budesonide for primary biliary cholangitis (PBC) in the seven major markets and China. A detailed picture of the budesonide for PBC in the 7MM + China, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China for the study period 2019-2032 is provided in this report along with a detailed description of the budesonide for PBC.
The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the budesonide market forecast analysis for PBC in the 7MM and China, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PBC.
Drug Summary
Budesonide, a corticosteroid with an extensive first-pass hepatic metabolism appeared promising for the treatment of PBC. The aim of this study was to evaluate the safety and estimate the efficacy of budesonide in patients with PBC, who have shown a suboptimal response to UDCA.
Budesonide Clinical Assessment
The report provides the clinical trials information of budesonide for PBC covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
Key Questions Answered
Key Topics Covered:
1. Report Introduction
2. Budesonide Overview in primary biliary cholangitis (PBC)
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and efficacy
2.3. Regulatory Milestones
2.4. Other Developmental Activities
2.5. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. Budesonide Market Assessment
5.1. Market Outlook of Budesonide in primary biliary cholangitis (PBC)
5.2. 7MM and China Analysis
5.2.1. Market Size of Budesonide in the 7MM and China for primary biliary cholangitis (PBC)
5.3. Country-wise Market Analysis
5.3.1. Market Size of Budesonide in the United States for primary biliary cholangitis (PBC)
5.3.2. Market Size of Budesonide in Germany for primary biliary cholangitis (PBC)
5.3.3. Market Size of Budesonide in France for primary biliary cholangitis (PBC)
5.3.4. Market Size of Budesonide in Italy for primary biliary cholangitis (PBC)
5.3.5. Market Size of Budesonide in Spain for primary biliary cholangitis (PBC)
5.3.6. Market Size of Budesonide in the United Kingdom for primary biliary cholangitis (PBC)
5.3.7. Market Size of Budesonide in Japan for primary biliary cholangitis (PBC)
5.3.8. Market Size of Budesonide in China for primary biliary cholangitis (PBC)
6. SWOT Analysis
7. Analysts' Views
8. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/s7v70r
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900